Wednesday, May 31, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Biosecurity

UC Irvine to Develop Q Fever Vaccine

by Global Biodefense Staff
March 28, 2016
Q Fever - Coxiella Burnetii

Q Fever - Coxiella BurnetiiThe Defense Threat Reduction Agency (DTRA) has awarded a University of California, Irvine scientific team an $8 million contract to help develop a new vaccine for Q fever.

Caused by the Coxiella burnetii bacterium, Q fever is a highly infectious agent common among livestock. It has a history of being aerosolized for use in biological warfare and is considered a potential bioterrorism weapon.

Q fever is also a public health threat; a 2007-10 outbreak in the Netherlands affected thousands of people. Symptoms include high fever, nausea, severe headache and abdominal pain. It is rarely fatal.

The development effort is led by infectious diseases researchers Philip Felgner and Aaron Esser-Kahn.

“The current vaccine for Q fever is effective but has severe side effects that limit its widespread use,” said Felgner, an adjunct professor of medicine at UC Irvine. “It’s a high priority that this vaccine be administered to members of the armed forces. Consequently, the military is interested in developing an alternative protective vaccine that’s safer and does not cause adverse reactions.”

Felgner will use an approach he pioneered at UC Irvine to create whole proteome microarrays to discover immune response-activating antigen proteins that may be effective as a vaccine. Additionally, he’ll collaborate with Esser-Kahn, assistant professor of chemistry, whose group will develop synthetic agents that can boost and control the immune response to these proteins.

Felgner said this dual method may be applicable in creating more vaccines important to the military and general public health, adding that this is an opportunity for the Department of Defense to test these methods for their potential use against other infectious diseases.

After identifying the target proteins, Felgner will work with the U.S. Army Medical Research Institute of Infectious Diseases at Fort Detrick in Maryland on next-stage animal studies of a candidate vaccine.

The project is a successful outgrowth of the Pacific Southwest Regional Center of Excellence at UC Irvine, one of only 11 National Institutes of Health-funded research sites dedicated to countering threats from bioterrorism agents and emerging infectious diseases. UC Irvine received $85 million for this effort, which was led by Dr. Alan Barbour, professor of microbiology & molecular genetics. The federal program ended in 2015.

Image courtesy of NIAID, adapted.

Tags: AwardsBioterrorismQ FeverSynthetic BiologyVaccines

Related Posts

Vials of finished vaccines
Funding News

UK Biomanufacturing Fund to Bolster Supply Chain Resilience and Pandemic Preparedness

May 26, 2023
Aptitude Awarded Up to $54M BARDA Funding for At-Home Diagnostics
Industry News

Aptitude Awarded Up to $54M BARDA Funding for At-Home Diagnostics

April 20, 2023
Medical Countermeasures

Scientists Design Molecule to Slow SARS-Cov-2 Infection

March 29, 2023
Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA
Funding News

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Load More

Latest News

Vials of finished vaccines

UK Biomanufacturing Fund to Bolster Supply Chain Resilience and Pandemic Preparedness

May 26, 2023
Dr. Sen Pei Discusses Challenges in Forecasting Antimicrobial Resistance

Dr. Sen Pei Discusses Challenges in Forecasting Antimicrobial Resistance

April 26, 2023
Biodefense Headlines – 25 April 2023

Biodefense Headlines – 25 April 2023

April 25, 2023
Aptitude Awarded Up to $54M BARDA Funding for At-Home Diagnostics

Aptitude Awarded Up to $54M BARDA Funding for At-Home Diagnostics

April 20, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2023 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2023 Stemar Media Group LLC

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are okay with it.OkPrivacy policy